Novel tools to quantify total, phospho-Ser129 and aggregated alpha-synuclein in the mouse brain

Abstract Assays for quantifying aggregated and phosphorylated (S129) human α-synuclein protein are widely used to evaluate pathological burden in patients suffering from synucleinopathy disorders. Many of these assays, however, do not cross-react with mouse α-synuclein or exhibit poor sensitivity fo...

Full description

Saved in:
Bibliographic Details
Main Authors: Benjamin Guy Trist, Courtney Jade Wright, Alejandra Rangel, Louise Cottle, Asheeta Prasad, Nanna Møller Jensen, Hjalte Gram, Nicolas Dzamko, Poul Henning Jensen, Deniz Kirik
Format: Article
Language:English
Published: Nature Portfolio 2024-11-01
Series:npj Parkinson's Disease
Online Access:https://doi.org/10.1038/s41531-024-00830-y
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850062329968852992
author Benjamin Guy Trist
Courtney Jade Wright
Alejandra Rangel
Louise Cottle
Asheeta Prasad
Nanna Møller Jensen
Hjalte Gram
Nicolas Dzamko
Poul Henning Jensen
Deniz Kirik
author_facet Benjamin Guy Trist
Courtney Jade Wright
Alejandra Rangel
Louise Cottle
Asheeta Prasad
Nanna Møller Jensen
Hjalte Gram
Nicolas Dzamko
Poul Henning Jensen
Deniz Kirik
author_sort Benjamin Guy Trist
collection DOAJ
description Abstract Assays for quantifying aggregated and phosphorylated (S129) human α-synuclein protein are widely used to evaluate pathological burden in patients suffering from synucleinopathy disorders. Many of these assays, however, do not cross-react with mouse α-synuclein or exhibit poor sensitivity for this target, which is problematic considering the preponderance of mouse models at the forefront of pre-clinical α-synuclein research. In this project, we addressed this unmet need by reformulating two existing AlphaLISA® SureFire® Ultra™ total and pS129 α-synuclein assay kits to yield robust and ultrasensitive (LLoQ ≤ 0.5 pg/mL) quantification of mouse and human wild-type and pS129 α-synuclein protein. We then employed these assays, together with the BioLegend α-synuclein aggregate ELISA, to assess α-synuclein S129 phosphorylation and aggregation in different mouse brain tissue preparations. Overall, we highlight the compatibility of these new immunoassays with rodent models and demonstrate their potential to advance knowledge surrounding α-synuclein phosphorylation and aggregation in synucleinopathies.
format Article
id doaj-art-f576a04dee31405487e4e7a89a22aae6
institution DOAJ
issn 2373-8057
language English
publishDate 2024-11-01
publisher Nature Portfolio
record_format Article
series npj Parkinson's Disease
spelling doaj-art-f576a04dee31405487e4e7a89a22aae62025-08-20T02:49:56ZengNature Portfolionpj Parkinson's Disease2373-80572024-11-0110111410.1038/s41531-024-00830-yNovel tools to quantify total, phospho-Ser129 and aggregated alpha-synuclein in the mouse brainBenjamin Guy Trist0Courtney Jade Wright1Alejandra Rangel2Louise Cottle3Asheeta Prasad4Nanna Møller Jensen5Hjalte Gram6Nicolas Dzamko7Poul Henning Jensen8Deniz Kirik9Charles Perkins Centre, School of Medical Sciences, Faculty of Medicine and Health, The University of SydneyCharles Perkins Centre, School of Medical Sciences, Faculty of Medicine and Health, The University of SydneyCharles Perkins Centre, School of Medical Sciences, Faculty of Medicine and Health, The University of SydneyCharles Perkins Centre, School of Medical Sciences, Faculty of Medicine and Health, The University of SydneyCharles Perkins Centre, School of Medical Sciences, Faculty of Medicine and Health, The University of SydneyDepartment of Biomedicine, Aarhus UniversityDepartment of Biomedicine, Aarhus UniversityBrain and Mind Centre, School of Medical Sciences, Faculty of Medicine and Health, The University of SydneyDepartment of Biomedicine, Aarhus UniversityCharles Perkins Centre, School of Medical Sciences, Faculty of Medicine and Health, The University of SydneyAbstract Assays for quantifying aggregated and phosphorylated (S129) human α-synuclein protein are widely used to evaluate pathological burden in patients suffering from synucleinopathy disorders. Many of these assays, however, do not cross-react with mouse α-synuclein or exhibit poor sensitivity for this target, which is problematic considering the preponderance of mouse models at the forefront of pre-clinical α-synuclein research. In this project, we addressed this unmet need by reformulating two existing AlphaLISA® SureFire® Ultra™ total and pS129 α-synuclein assay kits to yield robust and ultrasensitive (LLoQ ≤ 0.5 pg/mL) quantification of mouse and human wild-type and pS129 α-synuclein protein. We then employed these assays, together with the BioLegend α-synuclein aggregate ELISA, to assess α-synuclein S129 phosphorylation and aggregation in different mouse brain tissue preparations. Overall, we highlight the compatibility of these new immunoassays with rodent models and demonstrate their potential to advance knowledge surrounding α-synuclein phosphorylation and aggregation in synucleinopathies.https://doi.org/10.1038/s41531-024-00830-y
spellingShingle Benjamin Guy Trist
Courtney Jade Wright
Alejandra Rangel
Louise Cottle
Asheeta Prasad
Nanna Møller Jensen
Hjalte Gram
Nicolas Dzamko
Poul Henning Jensen
Deniz Kirik
Novel tools to quantify total, phospho-Ser129 and aggregated alpha-synuclein in the mouse brain
npj Parkinson's Disease
title Novel tools to quantify total, phospho-Ser129 and aggregated alpha-synuclein in the mouse brain
title_full Novel tools to quantify total, phospho-Ser129 and aggregated alpha-synuclein in the mouse brain
title_fullStr Novel tools to quantify total, phospho-Ser129 and aggregated alpha-synuclein in the mouse brain
title_full_unstemmed Novel tools to quantify total, phospho-Ser129 and aggregated alpha-synuclein in the mouse brain
title_short Novel tools to quantify total, phospho-Ser129 and aggregated alpha-synuclein in the mouse brain
title_sort novel tools to quantify total phospho ser129 and aggregated alpha synuclein in the mouse brain
url https://doi.org/10.1038/s41531-024-00830-y
work_keys_str_mv AT benjaminguytrist noveltoolstoquantifytotalphosphoser129andaggregatedalphasynucleininthemousebrain
AT courtneyjadewright noveltoolstoquantifytotalphosphoser129andaggregatedalphasynucleininthemousebrain
AT alejandrarangel noveltoolstoquantifytotalphosphoser129andaggregatedalphasynucleininthemousebrain
AT louisecottle noveltoolstoquantifytotalphosphoser129andaggregatedalphasynucleininthemousebrain
AT asheetaprasad noveltoolstoquantifytotalphosphoser129andaggregatedalphasynucleininthemousebrain
AT nannamøllerjensen noveltoolstoquantifytotalphosphoser129andaggregatedalphasynucleininthemousebrain
AT hjaltegram noveltoolstoquantifytotalphosphoser129andaggregatedalphasynucleininthemousebrain
AT nicolasdzamko noveltoolstoquantifytotalphosphoser129andaggregatedalphasynucleininthemousebrain
AT poulhenningjensen noveltoolstoquantifytotalphosphoser129andaggregatedalphasynucleininthemousebrain
AT denizkirik noveltoolstoquantifytotalphosphoser129andaggregatedalphasynucleininthemousebrain